Abstract 1673P
Background
There is still a profound lack of efficient therapeutic strategies against pancreatic or other periampullary adenocarcinoma. Surgery is seldom possible, leaving palliative chemotherapy the only option for most patients. Chemotherapy treatment is however often accompanied by serious side-effects, and the identification of biomarkers for early prediction of disease and treatment-associated symptoms could help alleviate patient suffering. This study investigated the dynamic interrelationship between immune-related serum proteins, routine biomarkers and health-related quality of life (HRQoL) factors during chemotherapy treatment of patients enrolled in the prospective, observational study Chemotherapy, Host response And Molecular dynamics in Periampullary cancer (CHAMP).
Methods
Proximity extension assay was applied to analyse 92 immune-associated proteins in longitudinal serum samples from 75 patients, 18 being treated with adjuvant and 57 with palliative intent. HRQoL data were available from all patients at baseline (BL), from 41 patients at three months, and from 23 patients at six months.
Results
Levels of 8 proteins; CCL23, CD4, CD28, DCN, Gal-1, GZMB, GZMH and MMP7 were strongly correlated (Spearman´s Rho ≤-0.6 or ≥0.6) with various symptoms (insomnia, dyspnea, cognitive and emotional functioning) during treatment. Associations between routine laboratory parameters albumin, CA19-9, CEA and CRP and HRQoL were overall weaker. None of the investigated proteins were associated with pain.
Conclusions
This is, to our knowledge, the first study exploring associations between serum biomarkers and HRQoL in patients with pancreatic or other periampullary cancer, and some findings merit further validation. The proteoglycan decorin (DCN) is of particular interest as it has been linked to conditions such as Alzheimer’s disease and schizophrenia. Chemotherapy is known to cause persistent cognitive dysfunction with effects on memory and executive function, referred to as “chemo brain”. It would therefore be of great value to identify biomarkers for early detection and management of this debilitating condition.
Clinical trial identification
NCT03724994.
Editorial acknowledgement
Legal entity responsible for the study
Region Skåne.
Funding
This work is supported by peer reviewed grants from the Swedish Research Council (grant number 2015-03598 and 2018-02441), the Swedish Cancer Society (grant number CAN 2018/418 and 21 1596 Pj), the SjöbergFoundation, the Lennart GlansFoundation, BioCARE, the Mrs Berta KampradFoundation, the Ingrid and Sverker PerssonFoundation, the Faculty of Medicine, Lund University, Governmental Funding of Clinical Research (ALF), and Skåne University Hospital Donations and Funds.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1589P - Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Presenter: Niels Guchelaar
Session: Poster session 22
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22